 |
|
Multiple Endocrine Neoplasia Type 2
Evaluation of the Genotype-Phenotype Relationship
Linwah Yip, MD;
Gilbert J. Cote, PhD;
Suzanne E. Shapiro, MS;
Gregory D. Ayers, MS;
Cynthia E. Herzog, MD;
Rena V. Sellin, MD;
Steven I. Sherman, MD;
Robert F. Gagel, MD;
Jeffrey E. Lee, MD;
Douglas B. Evans, MD
Arch Surg. 2003;138:409-416.
Hypothesis Multiple endocrine neoplasia type 2 (MEN 2) is caused by RET proto-oncogene mutations and has a strong penetrance for medullary thyroid carcinoma (MTC). Subtypes are defined by the presence or absence of pheochromocytomas, hyperparathyroidism, and characteristic clinical stigmas. We hypothesize that specific RET mutations correlate with the MEN 2 phenotype and aggressiveness of MTC.
Design Review of endocrine surgery database from 1951 through 2002.
Setting Tertiary referral center.
Patients Eighty-six patients from 47 kindreds were identified with MEN 2A, MEN 2B, or familial MTC. Patients were classified into 3 RET mutation risk groups: level 1, low risk for MTC (codons 609, 768, 790, 791, 804, and 891); level 2, intermediate risk (codons 611, 618, 620, and 634); and level 3, highest risk (codons 883 and 918).
Main Outcome Measures Stage of MTC at diagnosis and at last follow-up and frequency of pheochromocytomas and hyperparathyroidism.
Results RET analysis was complete for 71 patients from 39 kindreds. Multivariate analysis identified an increased likelihood of stage III or IV MTC at diagnosis with increasing age (odds ratio, 1.12 per year of age at thyroidectomy; 95% confidence interval, 1.07-1.17; P<.001) and increasing risk group (odds ratio, 14.23 per incremental increase in MTC risk group from 1 to 3; 95% confidence interval, 3.05-66.55; P<.001). Pheochromocytomas were found in 21 patients from 12 kindreds; 20 of 21 patients had codon 634 or 918 mutations. Hyperparathyroidism was found in 10 patients from 7 kindreds; 7 of 10 patients had codon 634 mutations.
Conclusion Specific RET mutations predict the phenotypic expression of disease and the MTC aggressiveness in patients with MEN 2, guiding the timing of thyroidectomy and screening for pheochromocytoma.
From the Departments of Surgical Oncology (Drs Yip, Lee, and Evans and Ms Shapiro), Endocrine Neoplasia and Hormonal Disorders (Drs Cote, Sellin, Sherman, and Gagel), Biostatistics (Mr Ayers), and Pediatrics (Dr Herzog), The University of Texas M. D. Anderson Cancer Center, Houston.
RELATED ARTICLE
This Month in Archives of Surgery
Arch Surg. 2003;138(4):353.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Uncommon association of germline mutations of RET proto-oncogene and CDKN2A gene
Foppiani et al.
Eur J Endocrinol 2008;158:417-422.
ABSTRACT
| FULL TEXT
Failure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think?
Wray et al.
Ann. Surg. Oncol. 2008;15:293-301.
ABSTRACT
| FULL TEXT
Pheochromocytoma: an update on genetics and management
Karagiannis et al.
Endocr Relat Cancer 2007;14:935-956.
ABSTRACT
| FULL TEXT
Surgical Management of Familial Hyperparathyroidism
Evans et al.
Ann. Surg. Oncol. 2007;14:1525-1527.
FULL TEXT
Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype.
Frank-Raue et al.
Eur J Endocrinol 2006;155:229-236.
ABSTRACT
| FULL TEXT
Molecular Implications of RET Mutations for Pheochromocytoma Risk in Multiple Endocrine Neoplasia 2.
GUJRAL and MULLIGAN
Ann. N. Y. Acad. Sci. 2006;1073:234-240.
ABSTRACT
| FULL TEXT
Risk-Oriented Approach to Hereditary Adrenal Pheochromocytoma.
MACHENS et al.
Ann. N. Y. Acad. Sci. 2006;1073:417-428.
ABSTRACT
| FULL TEXT
Paraganglioma--all in the family.
Young and Abboud
J. Clin. Endocrinol. Metab. 2006;91:790-792.
FULL TEXT
Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors
Papadimitrakopoulou et al.
Clin. Cancer Res. 2005;11:4151-4159.
ABSTRACT
| FULL TEXT
Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic
Jindrichova et al.
J Endocrinol 2004;183:257-265.
ABSTRACT
| FULL TEXT
A Novel Germ-Line Point Mutation in RET Exon 8 (Gly533Cys) in a Large Kindred with Familial Medullary Thyroid Carcinoma
Alvares Da Silva et al.
J. Clin. Endocrinol. Metab. 2003;88:5438-5443.
ABSTRACT
| FULL TEXT
|
